USANA
October 25, 2022
USANA Health Sciences reported third-quarter 2022 net sales of 233 million dollars, down 15 percent from 274 million dollars a year earlier and down 9 percent in constant currency. Currency reduced sales by about 15 million dollars. Diluted earnings per share fell to 0.78 dollars from 1.36 dollars.
Active customers declined 18 percent to 474,000. Asia Pacific generated 183 million dollars, or 78 percent of sales, including 110 million dollars from Greater China, while the Americas and Europe region contributed 51 million dollars. The company ended the quarter with 247 million dollars in cash and no debt.
USANA lowered its full-year outlook to net sales of 955 million to 975 million dollars and diluted EPS of 3.15 to 3.40 dollars, down from a prior sales range of 1.015 billion to 1.065 billion dollars. Chief executive Kevin Guest said new incentives and promotions were being rolled out to re-engage customers and associates.